-+ 0.00%
-+ 0.00%
-+ 0.00%
BioHarvest Q3 2026 operating loss more than triples year over year to USD 3 million
Share
Listen to the news
BioHarvest Q3 2026 operating loss more than triples year over year to USD 3 million
  • BioHarvest Sciences’ Q3 2026 net loss widened 32% year over year to USD 3.3 million.
  • Revenue fell 13% year over year to USD 7.9 million, reflecting moderated customer acquisition and CDMO development revenue timing.
  • Management is prioritizing cash preservation, controlled VINIA growth and CDMO programs with near-term manufacturing potential.
  • Limited production under the fragrance supply agreement could begin in Q1 2027, with anticipated revenue of USD 20–30 million in 2027–2028.
  • Full-year 2026 revenue is now expected at USD 32–33.5 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611120600NEWSFILECNPR____20261112_323713_1) on November 12, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending